{"id":24188,"date":"2024-07-26T08:54:48","date_gmt":"2024-07-26T12:54:48","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=24188"},"modified":"2026-04-26T14:41:06","modified_gmt":"2026-04-26T18:41:06","slug":"is-chiral-switching-still-relevant-in-todays-pricing-control-scenario","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/is-chiral-switching-still-relevant-in-todays-pricing-control-scenario\/","title":{"rendered":"Chiral Switching Is Dead as a Patent Play. Here’s Where It Still Makes Money."},"content":{"rendered":"\n

Executive Summary<\/strong><\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Chiral switching built billion-dollar franchises in the 1990s and early 2000s. The model was straightforward: isolate the active enantiomer from a racemic mixture, file new composition-of-matter and method-of-use patents on the single enantiomer, market it as a next-generation product at a premium, and buy another decade of exclusivity before the original drug went generic. AstraZeneca ran this play with esomeprazole (Nexium) against omeprazole (Prilosec). Forest Laboratories ran it with escitalopram (Lexapro) against citalopram (Celexa). UCB ran it with levocetirizine (Xyzal) against cetirizine (Zyrtec).<\/p>\n\n\n\n

That window is largely closed. The Inflation Reduction Act’s Medicare drug price negotiation provisions, IRA-driven rebate dynamics, and the hardening of NICE, IQWiG, and HAS methodology frameworks have collectively dismantled the economic case for switches pursued primarily to extend IP life. Today, a chiral switch must justify itself on clinical grounds that survive a full QALY analysis, a comparative effectiveness dossier, and increasingly, a budget impact model granular enough to satisfy a regional German Gemeinsamer Bundesausschuss (G-BA) subcommittee.<\/p>\n\n\n\n

This piece breaks down exactly where chiral switching still delivers IP and commercial value, where it does not, and how IP teams and portfolio managers should be stress-testing any switch candidate sitting in their pipeline right now.<\/p>\n\n\n\n

\n\n\n\n

1. The Chemistry Behind the Strategy: Why Chirality Matters to IP Teams<\/strong><\/h2>\n\n\n\n

1.1 Stereochemistry and Pharmacological Asymmetry<\/strong><\/h3>\n\n\n\n

A chiral molecule exists as two non-superimposable mirror-image forms called enantiomers, designated R and S (or historically d and l). Biological targets, from GPCRs to enzyme active sites, are themselves chiral environments built from L-amino acids. That structural asymmetry means the two enantiomers of a drug molecule routinely show dramatically different binding affinities, metabolic fates, and toxicity profiles.<\/p>\n\n\n\n

The textbook case is thalidomide. The R-enantiomer carried the sedative and anti-emetic activity while the S-enantiomer caused teratogenicity. What makes thalidomide a poor teaching example for chiral switching strategy is that the two enantiomers interconvert in vivo, so isolating one provides no safety advantage. That interconversion problem — termed racemization — is the first technical kill criterion any IP team needs to apply to a switch candidate. If the isolated enantiomer racemizes under physiological pH and temperature, the entire development rationale collapses before it reaches an IND.<\/p>\n\n\n\n

When racemization is not an issue, the pharmacokinetic advantages of a single enantiomer can be substantial. Racemic mixtures contain one enantiomer that may compete with the active form for protein binding, cytochrome P450 metabolism, or transporter-mediated uptake without contributing therapeutic effect. Eliminating the pharmacologically inert or less active enantiomer can produce a drug with a cleaner PK profile, a tighter dose-response relationship, and sometimes a meaningfully reduced adverse effect burden.<\/p>\n\n\n\n

1.2 IP Architecture of a Chiral Switch: What You Actually Own<\/strong><\/h3>\n\n\n\n

The IP position of a chiral switch is more layered and more fragile than it appears on first review. The racemic mixture is typically covered by an expired or expiring composition-of-matter patent. The new enantiomer can support a fresh composition-of-matter patent — but only if the enantiomer itself was not previously disclosed or obvious from the racemic patent. In re Dillon (Fed. Cir. 1990) established that structural similarity does not automatically defeat novelty, but the obvious-to-try doctrine, particularly post-KSR International v. Teleflex (2007), has made obviousness challenges to enantiomer patents substantially more successful.<\/p>\n\n\n\n

Beyond composition-of-matter claims, a switch strategy typically stacks method-of-use patents covering specific indications, formulation patents covering the salt form, polymorph, or delivery system, and process patents covering the stereospecific synthesis route. Each layer adds to the Orange Book listing and extends the Paragraph IV litigation exposure window for generic filers. For Hatch-Waxman purposes, a 30-month stay triggered by a Paragraph IV certification against any listed Orange Book patent gives the innovator meaningful time to litigate, even if the underlying enantiomer patent is ultimately held invalid.<\/p>\n\n\n\n

The IP valuation of a chiral switch therefore is not a single patent — it is a patent cluster. A drug like escitalopram, which held U.S. market exclusivity well past Celexa’s generic entry, illustrates this: Forest’s Orange Book listings included patents on the oxalate salt, specific crystalline forms, and method-of-use claims, each of which required individual Paragraph IV challenges from generic applicants including Teva, Mylan, and Ivax. That litigation complex, even when most patents ultimately fell, compressed generic entry timing.<\/p>\n\n\n\n

For portfolio managers assessing the IP value of a switch candidate, the relevant calculation is not the face value of the new composition-of-matter patent, but the net present value of delayed generic entry across the full Orange Book cluster, discounted for litigation risk and the probability that at least one key patent survives inter partes review (IPR) at the Patent Trial and Appeal Board (PTAB).<\/p>\n\n\n\n

1.3 Asymmetric Synthesis and Manufacturing IP<\/strong><\/h3>\n\n\n\n

A dimension of chiral switching that IP teams frequently undervalue is the process patent layer built around asymmetric synthesis. Producing a single enantiomer at commercial scale requires either chiral resolution (separating the enantiomers from a racemic mixture using chiral stationary phase chromatography or diastereomeric salt formation) or asymmetric synthesis (constructing the molecule with stereospecificity using chiral catalysts, enzymatic resolution, or chiral auxiliaries).<\/p>\n\n\n\n

Both routes generate patentable manufacturing processes. The Knowles-Noyori-Sharpless Nobel Prize chemistry — asymmetric hydrogenation and oxidation — underpins dozens of commercial chiral syntheses. Pfizer’s synthesis route for (S)-amlodipine, its chiral switch candidate from racemic amlodipine (Norvasc), relied on proprietary resolution technology. Although the switch ultimately did not achieve a major commercial relaunch, the process IP generated licensing revenue and formed the basis for supply agreements.<\/p>\n\n\n\n

For a generic applicant, designing around a strong process patent adds cost and development time even when the composition-of-matter patent has been invalidated. This makes the process patent layer strategically valuable beyond its face life, particularly when the asymmetric synthesis route is technically difficult to replicate.<\/p>\n\n\n\n

Key Takeaways — Section 1<\/strong><\/p>\n\n\n\n

The core IP thesis of a chiral switch rests on three layers: (1) a composition-of-matter patent on the isolated enantiomer, (2) method-of-use and formulation patents extending Orange Book coverage, and (3) process patents on the asymmetric synthesis or resolution technology. Each layer faces distinct challenge vectors. Enantiomer composition claims are vulnerable to KSR obviousness arguments. Method-of-use claims are vulnerable to skinny-label strategies by generic applicants. Process patents are vulnerable to design-around synthesis routes. A viable switch must hold enough of this cluster to generate a meaningful exclusivity window — currently estimated at five to seven years of protected market for a product with genuinely strong clinical differentiation, and two to four years for products where payer pushback limits price realization.<\/p>\n\n\n\n

\n\n\n\n

2. The Pricing Control Environment: Specific Mechanisms, Specific Consequences<\/strong><\/h2>\n\n\n\n

2.1 IRA Drug Price Negotiation and the Small-Molecule Cliff<\/strong><\/h3>\n\n\n\n

The Inflation Reduction Act’s negotiation provisions, now in force and surviving multiple legal challenges from manufacturers including Merck, Bristol-Myers Squibb, and Astellas, impose a structural disadvantage on small molecules relative to biologics. A small molecule becomes eligible for Medicare price negotiation nine years after approval; a biologic does not reach negotiation eligibility until thirteen years post-approval. This four-year differential directly reduces the commercial runway for small-molecule lifecycle strategies, including chiral switches, which are almost exclusively small molecules.<\/p>\n\n\n\n

For a chiral switch launched in year six or seven of the original drug’s lifecycle, the nine-year negotiation clock starts from the switch’s own approval date. This means a switch approved in 2024 enters Medicare price negotiation eligibility in 2033. If peak sales occur in years two through five post-launch, the impact of negotiated pricing on the tail end of exclusivity is less severe. But for switches that depend on sustained pricing to justify their development investment, the compressed timeline significantly changes NPV calculations.<\/p>\n\n\n\n

Portfolio managers should be running dual-scenario NPV models for any small-molecule switch: one with current Medicare pricing intact through peak exclusivity, and one discounting revenue from year nine onward at the statutory maximum fair price ceiling (which CMS sets at 40 to 75 percent below non-federal average manufacturer price for highly extended products).<\/p>\n\n\n\n

2.2 The G-BA AMNOG Process and the German Benchmark Problem<\/strong><\/h3>\n\n\n\n

Germany’s Arzneimittelmarktneuordnungsgesetz (AMNOG) framework, in effect since 2011, requires all newly launched drugs to demonstrate ‘zusatznutzen’ — additional benefit — against an appropriate comparator therapy within twelve months of launch. The G-BA subcommittee assessment directly determines the price corridor in subsequent GKV negotiations. A drug rated with ‘no additional benefit’ faces mandatory reference pricing to the generic comparator class.<\/p>\n\n\n\n

For a chiral switch, this is frequently a fatal commercial constraint. The comparator the G-BA assigns is typically the racemic predecessor at generic prices, which by the time a switch launches are often 80 to 90 percent below original brand price. Unless the switch demonstrates statistically significant and clinically meaningful superiority on patient-relevant endpoints — reduction in serious adverse events, improvement in mortality or major morbidity, or measurable improvement in patient-reported outcomes — the AMNOG rating lands at ‘no additional benefit,’ and the negotiated price collapses toward generic parity.<\/p>\n\n\n\n

Escitalopram avoided this fate partly because Celexa’s generic wave hit the U.S. market in 2003, and the IQWiG methodology was not operational in its current form until 2011. A structurally identical switch launched today against a racemic drug with established generic competition would face a G-BA dossier requirement demanding data from a randomized controlled trial comparing the single enantiomer against the generic racemate, powered to detect differences in hard clinical endpoints. That trial would cost $50 million to $150 million to run, materially altering the development economics for a product category historically justified by lower R&D spend than a new chemical entity.<\/p>\n\n\n\n

2.3 NICE and the QALY Threshold: Where Chiral Switches Fail the Math<\/strong><\/h3>\n\n\n\n

NICE evaluates cost-effectiveness against a threshold of \u00a320,000 to \u00a330,000 per quality-adjusted life year (QALY). For a chiral switch priced at a premium above the racemic comparator, the incremental cost-effectiveness ratio (ICER) must land below this ceiling to receive a positive recommendation. The math works only when two conditions hold simultaneously: the clinical benefit is quantifiable in QALYs, and the QALY gain is large enough at the proposed price differential to fall inside the threshold.<\/p>\n\n\n\n

Most chiral switches do not clear this bar. Consider a hypothetical: a new S-enantiomer of an existing CNS drug that reduces somnolence rates from 18 percent to 11 percent relative to the racemic form. This is clinically real — levocetirizine’s reduced sedation profile relative to cetirizine represents exactly this type of difference. But converting a 7-percentage-point reduction in somnolence into QALYs requires validated utility mapping, and the resulting QALY gain may be 0.02 to 0.05 per patient-year. At a price premium of \u00a3500 per year, that produces an ICER of \u00a310,000 to \u00a325,000 — potentially inside the NICE threshold. At a \u00a32,000 annual premium, the ICER exceeds \u00a340,000 and the recommendation turns negative.<\/p>\n\n\n\n

This arithmetic explains why successful chiral switches cluster in two categories: those with safety advantages severe enough to produce meaningful QALY gains (such as reductions in QTc prolongation, hepatotoxicity, or serious CNS adverse events), and those where the racemic comparator is not available generically at time of switch launch, allowing a price comparison against the branded racemate rather than its generic equivalent.<\/p>\n\n\n\n

2.4 Reference Pricing Cascades Across EU Markets<\/strong><\/h3>\n\n\n\n

External reference pricing across EU member states creates a cascade dynamic that particularly constrains chiral switch pricing. Germany, France, Italy, Spain, and Belgium are among the most commonly referenced countries. A price concession negotiated under AMNOG in Germany becomes the ceiling referenced in Italy’s AIFA negotiations. An unfavorable HAS assessment in France propagates into Spanish AEMPS reference calculations. This means a chiral switch that fails to achieve ‘zusatznutzen’ in Germany does not just lose Germany — it depresses the reimbursable price across a portfolio of EU markets that collectively represent 30 to 40 percent of global ex-U.S. revenue for most products.<\/p>\n\n\n\n

IP teams and commercial strategy leads need to map the reference pricing cascade before a switch candidate enters Phase 2 clinical development, not at the launch planning stage. The clinical trial design must generate data capable of satisfying the G-BA dossier requirements (active comparator RCT, patient-relevant endpoints, pre-specified subgroup analyses for response heterogeneity) simultaneously with the FDA’s 505(b)(2) evidence requirements. Running sequential trials — one for FDA, one for HTA — doubles development cost and delays EU launch by two to three years, during which generic racemic competition is already eroding the price baseline.<\/p>\n\n\n\n

Key Takeaways — Section 2<\/strong><\/p>\n\n\n\n

The IRA nine-year Medicare negotiation clock compresses the tail-end commercial value of small-molecule switches. The G-BA AMNOG process imposes a hard clinical differentiation requirement that most switches cannot meet without large, expensive head-to-head trials. NICE QALY math works only when the adverse event profile improvement is severe enough to register as a meaningful utility gain at the proposed price premium. Reference pricing cascades mean a German AMNOG failure is effectively a European pricing failure. Any switch candidate that cannot survive these four filters simultaneously does not have a viable European commercial model.<\/p>\n\n\n\n

Investment Strategy — Section 2<\/strong><\/p>\n\n\n\n

Portfolio managers evaluating a company with a declared chiral switch program should request the HEOR (health economics and outcomes research) dossier before assigning pipeline value. If no pre-AMNOG scientific advice meeting has been held with the G-BA and no NICE scoping meeting is scheduled prior to Phase 3 initiation, the company has not yet confronted the pricing constraint. Apply a 40 to 60 percent haircut to the switch’s projected EU revenue until a completed AMNOG dossier is in hand.<\/p>\n\n\n\n

\n\n\n\n

3. Case Studies: IP Valuation and Commercial Outcomes Across the Spectrum<\/strong><\/h2>\n\n\n\n

3.1 Esomeprazole (Nexium): The Last Great Chiral Switch<\/strong><\/h3>\n\n\n\n

AstraZeneca’s development of esomeprazole from omeprazole represents the canonical chiral switch success, and also the most instructive illustration of why that success cannot be replicated today. Omeprazole (Prilosec) received FDA approval in 1989 and became one of the top-selling drugs globally. Its racemic mixture contained the S-enantiomer (esomeprazole) and the R-enantiomer, with CYP2C19 metabolizing both, though with different kinetics.<\/p>\n\n\n\n

AstraZeneca’s clinical argument for esomeprazole centered on pharmacokinetic superiority: the S-enantiomer had lower first-pass metabolism than the racemate in extensive metabolizers, producing higher and more consistent plasma concentrations and superior acid suppression by pAUC (percentage time gastric pH above 4). Clinical trials showed esomeprazole 40mg achieved greater intragastric pH control than omeprazole 20mg in head-to-head studies. The FDA approved esomeprazole in 2001 under the 505(b)(2) pathway.<\/p>\n\n\n\n

The IP valuation picture was formidable. AstraZeneca’s Orange Book listings for Nexium included the enantiomer composition patent (U.S. 5,714,504, expiring 2014), a magnesium salt formulation patent, and multiple method-of-use patents. Nexium reached peak U.S. sales of approximately $5.7 billion annually, making it the second-best-selling drug in the world in 2005. The IP cluster generated more than $30 billion in cumulative U.S. revenue before generic entry in 2014 following litigation settlements with Teva, Ranbaxy, and Dr. Reddy’s under the Hatch-Waxman framework.<\/p>\n\n\n\n

The reason this cannot be replicated today is structural. When esomeprazole launched in 2001, AMNOG did not exist. NICE’s technology appraisal program was in its infancy. Medicare did not negotiate drug prices. Generic omeprazole was not yet a fully commoditized $4 bottle at Walmart. All four of those conditions now hold, and they collectively eliminate the pricing environment that allowed Nexium to command a $4 to $6 per-pill premium over generic omeprazole for thirteen years.<\/p>\n\n\n\n

3.2 Escitalopram (Lexapro): Clinical Differentiation That Survived Scrutiny<\/strong><\/h3>\n\n\n\n

Forest Laboratories filed an NDA for escitalopram oxalate in 2002, six years after citalopram (Celexa) reached U.S. approval. The switch rested on a pharmacodynamically cleaner profile: escitalopram is the S-enantiomer of citalopram, and the R-enantiomer of citalopram demonstrates allosteric inhibitory activity at the serotonin transporter (SERT) that partially antagonizes the primary reuptake inhibition mechanism of the S-form. Isolating the S-enantiomer removes that allosteric competition, yielding more potent and selective SERT inhibition at lower doses.<\/p>\n\n\n\n

The clinical evidence for escitalopram’s superiority over citalopram was modest but real. Head-to-head trials showed numerically superior depression scale outcomes and a faster onset of antidepressant response. The drug’s cleaner receptor binding translated into a somewhat reduced drug-drug interaction burden via CYP2C19. Forest priced Lexapro at a significant premium over branded Celexa, and the product achieved peak U.S. sales of approximately $2.7 billion before Lundbeck’s original IP on citalopram expired and the broader market began collapsing toward generic.<\/p>\n\n\n\n

The IP architecture was aggressive. Multiple Paragraph IV challenges were filed against Orange Book-listed patents covering the oxalate salt, specific crystal forms, and dosing regimens. Teva, Mylan, and Ivax all filed ANDAs. Forest settled several of these with authorized generic agreements that effectively paid generic manufacturers to delay. The FTC investigated these settlements as reverse payments under the Actavis framework — the Supreme Court’s 2013 ruling in FTC v. Actavis that reverse-payment settlements can constitute antitrust violations. Forest ultimately paid $10 million to resolve FTC antitrust concerns.<\/p>\n\n\n\n

For IP teams, the Lexapro case illustrates both the power and the limits of the enantiomer patent cluster. The clinical story was sufficient to sustain a premium for several years. But the settlement costs, combined with the antitrust exposure from Actavis-era scrutiny, materially reduced the net IP value of the litigation strategy. Post-Actavis, any chiral switch lifecycle management plan that incorporates reverse-payment settlements must be evaluated against FTC challenge risk.<\/p>\n\n\n\n

3.3 Levocetirizine (Xyzal): Marginal Benefits, Durable Niche<\/strong><\/h3>\n\n\n\n

UCB launched levocetirizine (Xyzal) in the U.S. in 2007, twelve years after cetirizine (Zyrtec) received OTC approval in many markets. The pharmacological case was straightforward: cetirizine’s R-enantiomer carries most of the H1-receptor antagonist activity, while the S-enantiomer contributes primarily to sedation without antihistamine benefit. Removing the S-enantiomer produces a drug with equivalent antihistamine efficacy at half the dose and lower CNS sedation.<\/p>\n\n\n\n

The clinical evidence supporting levocetirizine’s reduced sedation was consistent across multiple trials, with somnolence rates of approximately 6 percent for levocetirizine 5mg versus 14 percent for cetirizine 10mg in direct comparisons. This is a real and patient-relevant difference, particularly for patients in occupational settings where daytime alertness matters. UCB obtained FDA approval via 505(b)(2) and initially marketed Xyzal as a prescription-only product despite cetirizine being available OTC.<\/p>\n\n\n\n

The prescription-only strategy was deliberate IP protection. By maintaining Rx status, UCB prevented direct generic substitution at retail pharmacies and retained formulary leverage with PBMs. When Xyzal’s key patents expired and generic levocetirizine entered in 2017, UCB had already transitioned the brand to OTC status (Xyzal Allergy 24HR), allowing a consumer market pivot.<\/p>\n\n\n\n

The IP valuation of Xyzal’s enantiomer patents was considerably lower than Nexium or Lexapro — peak branded U.S. sales reached approximately $270 million annually — but the switch generated meaningful IP life extension. The more instructive lesson is that a switch with genuinely quantifiable safety differentiation (6 percent versus 14 percent somnolence is a number you can put in a G-BA dossier) has a defensible commercial case even in a tighter pricing environment. The case for levocetirizine in a 2024 AMNOG submission would be difficult but not impossible, if the somnolence data were accompanied by a health economic model demonstrating reduced occupational accident risk or improved medication adherence.<\/p>\n\n\n\n

3.4 (S)-Amlodipine: The Switch That Didn’t Launch (And Why)<\/strong><\/h3>\n\n\n\n

Pfizer’s experience with (S)-amlodipine as a potential chiral switch from racemic amlodipine (Norvasc) is instructive precisely because the program did not advance to a major commercial launch in the U.S. Norvasc was one of the best-selling antihypertensives of the 1990s, and its calcium channel blocking activity resides primarily in the (S)-enantiomer. Pfizer had full awareness of this stereochemical fact. The R-enantiomer contributes essentially no antihypertensive activity.<\/p>\n\n\n\n

The scientific rationale for a switch existed. Some trials suggested (S)-amlodipine at half the racemic dose produced comparable blood pressure lowering with a slightly reduced peripheral edema burden, one of Norvasc’s most common adverse effects. But the clinical differentiation was marginal — edema rates moved by a few percentage points, not by a magnitude that would survive a QALY analysis at any meaningful price premium. Pfizer assessed the development economics and did not pursue a major U.S. regulatory filing for (S)-amlodipine as a proprietary product.<\/p>\n\n\n\n

Notably, (S)-amlodipine has been marketed in India by companies including Torrent Pharmaceuticals and Ajanta Pharma, under brands such as Asomex and S-Amlong. The Indian market context differs fundamentally: pricing is volume-driven, HTA frameworks are nascent, and the regulatory bar for clinical differentiation is lower. This illustrates an important market segmentation point — chiral switches with marginal clinical differentiation may retain commercial viability in emerging markets where value-based pricing mechanisms are not yet enforced, even when they cannot survive scrutiny in the U.S. or EU.<\/p>\n\n\n\n

Key Takeaways — Section 3<\/strong><\/p>\n\n\n\n

The historical cases reveal a clear gradient. Switches with robust pharmacokinetic or pharmacodynamic rationale and documented head-to-head clinical superiority (esomeprazole, escitalopram) generated billions in IP value but required a pricing environment that no longer exists. Switches with genuine but smaller safety differentiation (levocetirizine) can still generate meaningful commercial value if the adverse event reduction is quantifiable and the market access strategy accounts for the Rx-to-OTC lifecycle. Switches with marginal differentiation (S-amlodipine in the U.S.) fail the pricing screen regardless of the underlying chemistry. The India pathway represents a real but financially limited alternative for marginal switches.<\/p>\n\n\n\n

Investment Strategy — Section 3<\/strong><\/p>\n\n\n\n

When a company announces a chiral switch program, the relevant due diligence questions are: (1) What is the specific adverse event or PK parameter that differentiates the enantiomer, and is it quantifiable in a G-BA-ready dossier? (2) Has the company run an AMNOG pre-consultation, and what was the proposed comparator? (3) Is the racemic drug available generically in target markets? (4) What Orange Book patents are listed for the switch, and what is their IPR vulnerability at PTAB? If answers to questions 1 and 2 are vague and the answer to question 3 is ‘yes,’ the switch’s commercial model depends on U.S. market pricing dynamics alone, which are themselves now subject to IRA negotiation risk.<\/p>\n\n\n\n

\n\n\n\n

4. Evergreening Tactics Compared: Where Chiral Switching Sits in the Lifecycle Management Toolkit<\/strong><\/h2>\n\n\n\n

4.1 The Full Evergreening Toolkit<\/strong><\/h3>\n\n\n\n

Pharmaceutical lifecycle management draws on a spectrum of IP strategies, each with distinct clinical evidence requirements, regulatory pathways, patent claim structures, and payer scrutiny profiles. Chiral switching occupies a specific position in this spectrum that has shifted over the past decade.<\/p>\n\n\n\n

New formulation patents (extended-release, transdermal, abuse-deterrent) generate Orange Book listings with relatively lower clinical development cost but face aggressive FDA guidance requiring bioequivalence studies that generic applicants can replicate. New salt or polymorph patents are cheap to file but vulnerable to PTAB invalidity proceedings and are rarely sufficient alone to sustain reimbursement premium. Pediatric exclusivity under PREA (Pediatric Research Equity Act) grants six months of additional exclusivity appended to all unexpired patents and exclusivity periods — this applies to any drug including chiral switches and is frequently the most cost-efficient lifecycle management mechanism available. Indication expansion into new therapeutic areas can support independent clinical exclusivity periods and reset the commercial clock, but requires full Phase 3 programs. Fixed-dose combination (FDC) products generate new Orange Book listings and can qualify for new chemical entity (NCE) exclusivity if the combination is approved for the first time.<\/p>\n\n\n\n

Chiral switching historically outperformed most of these alternatives on the IP value-per-development-dollar metric, because the 505(b)(2) pathway allowed reliance on the safety and efficacy data of the racemic drug, reducing Phase 3 costs substantially. That advantage is now partially offset by the higher clinical differentiation hurdle imposed by HTA bodies.<\/p>\n\n\n\n

4.2 Chiral Switching vs. Indication Expansion: A Comparative Framework<\/strong><\/h3>\n\n\n\n

For an IP team deciding between a chiral switch and an indication expansion for lifecycle management, the decision tree runs through four variables: residual IP life on the racemic drug, availability of generic racemic competition in the target markets, probability of demonstrating clinical differentiation sufficient for HTA approval, and the Phase 3 cost differential.<\/p>\n\n\n\n

Where the racemic drug still holds active composition-of-matter protection, an indication expansion on the original molecule is typically more economical — it does not require manufacturing scale-up for stereospecific synthesis, it does not trigger new Paragraph IV litigation exposure on a separate Orange Book listing, and it can use the same API supply chain. Where the racemic drug has gone generic and the company seeks to establish a distinct product identity, a chiral switch with a meaningful clinical story may justify the investment, particularly if the switch can be positioned to a specialty segment where payer mix favors commercial insurance over Medicare and Medicaid.<\/p>\n\n\n\n

Indication expansion is the more strategically robust option in a post-IRA environment for most CNS and cardiovascular assets. Chiral switching retains an advantage in therapeutic areas where the adverse event profile of the racemate is well-documented, the mechanism of adverse event attributability to one enantiomer is understood, and head-to-head trial costs are manageable because the primary endpoint is a well-validated biomarker rather than a cardiovascular or mortality outcome requiring thousands of patient-years.<\/p>\n\n\n\n

4.3 The 505(b)(2) Pathway: Technical Requirements and Strategic Limits<\/strong><\/h3>\n\n\n\n

The 505(b)(2) pathway allows a sponsor to rely on FDA’s prior finding of safety and efficacy for the reference listed drug (RLD), supplemented by whatever new clinical data is required to bridge the differences between the RLD and the new product. For a chiral switch, the sponsor must characterize the enantiomeric purity, establish that the single enantiomer is safe (particularly ruling out safety signals not present with the racemate), and demonstrate efficacy through studies that may include PK bridging, PD studies, and in some cases abbreviated clinical trials.<\/p>\n\n\n\n

The FDA’s guidance on stereoisomers, including the 1992 policy statement on development of new stereoisomeric drugs, indicates that for drugs where one enantiomer is pharmacologically active and the other is essentially inert, PK and PD data may suffice without full Phase 3 trials. But this regulatory efficiency at FDA does not translate into HTA efficiency. The G-BA and NICE both require clinical endpoints in patient-relevant outcome domains, not just PK bridging. A company that optimizes its development program for 505(b)(2) FDA approval without simultaneously building an AMNOG-grade clinical package will arrive at launch with a U.S. approval and no viable European pricing.<\/p>\n\n\n\n

The correct development strategy for a 2020s chiral switch is to design a Phase 2\/3 program that satisfies all three requirements simultaneously: 505(b)(2) data bridging requirements for FDA, a randomized trial with an active racemic comparator arm and patient-relevant endpoints for the G-BA, and a health economic model with utility data capable of clearing a NICE ICER threshold. This three-track clinical design costs more than a pure 505(b)(2) program but costs less than running separate sequential trials and is the only approach that preserves global market optionality.<\/p>\n\n\n\n

Key Takeaways — Section 4<\/strong><\/p>\n\n\n\n

Chiral switching sits in the middle of the evergreening toolkit — more clinically intensive than formulation or polymorph patents, less costly than full indication expansion into a new therapeutic area. Its 505(b)(2) regulatory efficiency advantage has been partially neutralized by HTA bodies that do not accept PK bridging as adequate evidence for reimbursement decisions. The optimal development strategy for any contemporary switch candidate is a unified Phase 2\/3 design satisfying FDA 505(b)(2), G-BA AMNOG dossier, and NICE health economic requirements simultaneously, even though this raises per-trial cost relative to historical norms.<\/p>\n\n\n\n

\n\n\n\n

5. Screening Criteria: How to Evaluate a Chiral Switch Candidate Today<\/strong><\/h2>\n\n\n\n

5.1 The Pre-Development Kill Screen<\/strong><\/h3>\n\n\n\n

Before committing Phase 2 resources to a chiral switch candidate, IP and clinical teams should apply a sequential kill screen. A candidate that fails any criterion should be deprioritized unless a specific market context (pediatric indication, emerging market focus, or orphan designation) alters the calculus.<\/p>\n\n\n\n

The first criterion is pharmacological asymmetry. Does the active enantiomer demonstrate a minimum two-fold superiority in receptor binding affinity, IC50, or clinical PD effect versus the racemate at equivalent dose? If the difference is less than this threshold, the QALY gain at any defensible price premium will be too small to clear NICE criteria.<\/p>\n\n\n\n

The second criterion is in vivo stability. Does the isolated enantiomer maintain its configuration under physiological conditions, confirmed in in vitro metabolic stability assays and in vivo animal models? Enantiomers that racemize at physiological pH or via CYP450-mediated oxidation do not deliver the expected clinical differentiation.<\/p>\n\n\n\n

The third criterion is adverse event attributability. Is there a mechanistic explanation, supported by in vitro receptor binding data or metabolite profiling, for why the unwanted enantiomer causes specific adverse events? Without this mechanistic link, a clinical trial showing adverse event reduction will be vulnerable to alternative explanations and the G-BA will not attribute the benefit to the switch.<\/p>\n\n\n\n

The fourth criterion is generic competition status. Has the racemic drug gone generic in EU reference pricing countries? If it has, the price comparison in AMNOG negotiations will be against generic prices, and the switch must demonstrate clinical superiority sufficient to justify a price multiple of five to ten over generic — a bar that very few switches clear.<\/p>\n\n\n\n

The fifth criterion is trial cost feasibility. Can a head-to-head trial against the racemic comparator, powered to detect the expected clinical difference, be conducted in under 1,000 patients? Large cardiovascular outcome trials requiring five or more years of follow-up and five-figure patient enrollment are economically incompatible with chiral switch development economics.<\/p>\n\n\n\n

5.2 Therapeutic Areas Where Switches Retain Viability<\/strong><\/h3>\n\n\n\n

Four therapeutic categories maintain meaningful chiral switching viability in 2024 and 2025, based on the clinical differentiation profile, feasibility of hard endpoint trials, and payer willingness to differentiate on adverse event data.<\/p>\n\n\n\n

CNS and psychiatry represent the strongest residual opportunity. Adverse event differentiation in CNS drugs (sedation, weight gain, QTc prolongation, sexual dysfunction, withdrawal severity) is highly valued by patients and increasingly by payers who recognize downstream costs of non-adherence. The QALY utility mapping for major depressive disorder, anxiety disorders, and epilepsy is mature and well-validated, making it feasible to convert adverse event improvements into credible QALY estimates. Trial sizes for CNS efficacy endpoints are manageable.<\/p>\n\n\n\n

Analgesics and pain management represent a second viable area, particularly where one enantiomer of a racemic analgesic carries disproportionate abuse potential or respiratory depression risk. The opioid crisis has made payer and regulatory bodies unusually attentive to adverse event profiles of analgesics, and a switch with documented abuse-deterrent properties or reduced respiratory depression risk could command formulary differentiation.<\/p>\n\n\n\n

Oncology supportive care is a third area. Drugs used for chemotherapy-induced nausea, mucositis, or peripheral neuropathy have well-documented quality-of-life outcome instruments, making QALY translation feasible, and payers in oncology have historically accepted higher evidence thresholds for patient-relevant outcome claims.<\/p>\n\n\n\n

Ophthalmology represents a fourth niche, particularly for topically administered drugs where systemic exposure of one enantiomer drives systemic adverse events while the other enantiomer retains local therapeutic activity. The trial sizes are small, endpoints are validated, and payer dynamics in ophthalmology allow meaningful price differentiation for safety-improved products.<\/p>\n\n\n\n

5.3 Regulatory Interaction Strategy<\/strong><\/h3>\n\n\n\n

For candidates that survive the kill screen, the regulatory interaction strategy should be concurrent rather than sequential. A pre-IND Type B meeting with FDA’s CDER office of pharmaceutical sciences should address the specific 505(b)(2) bridging requirements. A G-BA early dialogue procedure should be requested simultaneously to establish the acceptable comparator arm and primary endpoint design. NICE scientific advice should be sought within the same twelve-month window to align the health economic modeling approach.<\/p>\n\n\n\n

The single most expensive mistake in chiral switch development is designing a Phase 3 trial optimized for FDA 505(b)(2) approval — typically a placebo-controlled trial with a surrogate PK or PD endpoint — that the G-BA then rejects as inadequate for AMNOG dossier purposes. This forces either an additional European trial (adding $50 to $100 million and two to three years) or a German market launch at generic reference prices. Early alignment of all three regulatory conversations is the most important cost-control measure available.<\/p>\n\n\n\n

Key Takeaways — Section 5<\/strong><\/p>\n\n\n\n

The five-criterion kill screen (pharmacological asymmetry, in vivo stability, adverse event attributability, generic competition status, trial cost feasibility) is the minimum pre-development discipline required to avoid committing Phase 2 resources to candidates without a viable global commercial path. CNS, analgesics, oncology supportive care, and ophthalmology are the four therapeutic areas where the clinical differentiation profile most frequently supports a viable switch. Concurrent FDA, G-BA, and NICE regulatory engagement from the earliest development stage is the primary lever for controlling development costs and preserving multi-market commercial optionality.<\/p>\n\n\n\n

Investment Strategy — Section 5<\/strong><\/p>\n\n\n\n

When evaluating early-stage companies with chiral switch programs, the presence of a concurrent regulatory interaction strategy across FDA, G-BA, and NICE is a positive signal. Its absence — particularly when a company describes a 505(b)(2) program with no mention of HTA engagement — suggests the management team is optimizing for regulatory approval rather than commercial viability. Adjust pipeline risk discount rates accordingly. Programs in CNS and ophthalmology should receive lower commercial risk discounts than cardiovascular or metabolic switches, where generic competition is more entrenched and head-to-head trial requirements are more expensive.<\/p>\n\n\n\n

\n\n\n\n

6. Chiral Switching and Biologics: A Structural Comparison<\/strong><\/h2>\n\n\n\n

6.1 Why the Analogy Breaks Down<\/strong><\/h3>\n\n\n\n

Some IP strategy discussions conflate chiral switching with what might be termed ‘biologic switching’ — the development of biosimilars or follow-on biologic products with modifications to the reference product intended to claim improved profiles. This conflation is structurally misleading. Chiral switching operates entirely within the small-molecule Hatch-Waxman framework, relies on composition-of-matter patents for its core exclusivity, and faces FDA’s 505(b)(2) pathway as its primary regulatory vehicle.<\/p>\n\n\n\n

Biologics, governed by the Biologics Price Competition and Innovation Act (BPCIA) and the 351(k) pathway, face a fundamentally different IP and regulatory environment. The ‘patent dance’ under BPCIA — the structured exchange of patent lists between reference product sponsor and biosimilar applicant — involves product, process, and formulation patents but no equivalent to the Paragraph IV Orange Book certification that makes Hatch-Waxman litigation so central to small-molecule strategy.<\/p>\n\n\n\n

The IRA’s thirteen-year negotiation eligibility threshold for biologics (versus nine years for small molecules) creates a structural incentive for pharmaceutical companies to develop lifecycle extensions as biologics where possible, rather than as small-molecule switches. This is one reason the industry’s lifecycle management attention has shifted toward subcutaneous formulations of IV biologics, extended half-life antibody modifications, and antibody-drug conjugate derivatives — all of which can claim biologic status and benefit from the longer negotiation exclusivity window.<\/p>\n\n\n\n

6.2 Where Chiral Strategy Intersects with Biologic Development: Chiral Linkers and ADCs<\/strong><\/h3>\n\n\n\n

One underappreciated intersection between chirality and biologic development is in antibody-drug conjugate (ADC) linker chemistry. ADCs deliver cytotoxic small-molecule payloads to tumor cells via antibody targeting. The linker connecting the antibody to the cytotoxic payload is frequently a small molecule with chiral centers, and the stereochemical configuration of the linker affects plasma stability, payload release kinetics, and the immunogenicity of the linker-payload fragment.<\/p>\n\n\n\n

Companies developing ADC platforms, including AstraZeneca (through its acquisition of Daiichi Sankyo’s ADC portfolio), Pfizer (through its acquisition of Seagen), and Immunomedics (acquired by Gilead), have filed composition-of-matter patents on specific linker enantiomers and diastereomers as part of their ADC IP strategies. These are not chiral switches in the classical sense — they are not switching from a racemate to an enantiomer for a standalone drug. But they represent an application of chirality-based IP strategy within a biologic development framework, and they are subject to composition-of-matter patent protection and PTAB challenge risk in the same way that small-molecule enantiomer patents are.<\/p>\n\n\n\n

For IP teams at companies with ADC programs, the stereochemical configuration of the linker and payload should be part of the patent claim drafting strategy from the earliest stage of platform development. Freedom-to-operate analysis against competitor ADC linker patents should explicitly cover enantiomeric and diastereomeric alternatives.<\/p>\n\n\n\n

Key Takeaways — Section 6<\/strong><\/p>\n\n\n\n

Chiral switching is a small-molecule strategy governed by Hatch-Waxman, and its IP mechanics do not translate directly to biologic development. The IRA’s favorable thirteen-year negotiation eligibility for biologics creates a structural incentive to pursue lifecycle extensions as biologics where scientifically feasible. ADC linker chemistry is an emerging domain where stereospecific IP strategy matters and where IP teams should be applying chiral composition-of-matter patent drafting discipline.<\/p>\n\n\n\n

\n\n\n\n

7. The Path Forward: Chiral Switching in a Value-Based Pricing World<\/strong><\/h2>\n\n\n\n

7.1 The Surviving Commercial Model<\/strong><\/h3>\n\n\n\n

Chiral switching survives as a viable commercial strategy in 2025 under a specific set of conditions that are considerably more demanding than those of a decade ago. The drug must be in a therapeutic area where adverse event differentiation generates measurable QALY utility. The adverse event attributable to the unwanted enantiomer must be mechanistically established, not simply observed. The head-to-head clinical trial must be feasible in cost and patient numbers. The global regulatory engagement strategy must satisfy FDA, G-BA, and NICE requirements from a single Phase 3 design.<\/p>\n\n\n\n

When all four conditions hold, a chiral switch can still generate a meaningful exclusivity window and a sustainable price premium — particularly in the U.S. specialty market where payer mix is more favorable and where direct-to-prescriber contracting with PBMs can protect formulary position even against generic racemic alternatives.<\/p>\n\n\n\n

7.2 Emerging Regulatory Considerations: FDA’s Evolving Stance on Enantiomers<\/strong><\/h3>\n\n\n\n

The FDA’s 1992 policy statement on stereoisomers established the basic framework for how the agency evaluates enantiomer applications. The policy has been supplemented by ICH Q8, Q9, and Q10 guidelines on pharmaceutical development, quality risk management, and pharmaceutical quality systems, which impose rigorous requirements on the characterization and control of chiral purity in the manufacturing process. Enantiomeric excess (ee) specifications in the drug substance monograph must be validated, and any drift in ee that produces racemization during storage must be characterized and controlled through shelf-life specifications.<\/p>\n\n\n\n

Regulatory risk around chiral purity failures — where a batch of the single enantiomer contains more than the specified limit of the unwanted enantiomer — is non-trivial. A manufacturing deviation that degrades enantiomeric purity below the NDA specification triggers a potential recall and a CMC (chemistry, manufacturing, and controls) supplement, with associated supply disruption costs. This operational risk should be factored into the NPV model for any switch candidate, particularly where the asymmetric synthesis route is sensitive to temperature or moisture.<\/p>\n\n\n\n

7.3 The Emerging Market Opportunity: A Separate Commercial Logic<\/strong><\/h3>\n\n\n\n

Emerging markets — India, Brazil, China, Southeast Asia — operate under pricing frameworks that differ structurally from the EU and U.S. models. HTA bodies in these markets are nascent. Reference pricing exists but is less rigorously enforced. Physician prescribing autonomy is greater, and payer pushback against branded products with modest clinical differentiation is weaker. In this context, a chiral switch with marginal adverse event improvement can sustain a price premium through physician preference, particularly when the company invests in CME (continuing medical education) programs that highlight the clinical distinction.<\/p>\n\n\n\n

This is the commercial logic behind the Indian market success of S-amlodipine under brands like Asomex and S-Amlong. It explains why Indian generic manufacturers including Sun Pharma, Cipla, and Torrent have filed and marketed single-enantiomer versions of drugs that did not achieve commercial launch as proprietary switches in the U.S. or EU. For a multinational company with a switch candidate that fails the G-BA and NICE screens, a licensing or supply agreement with an Indian or Brazilian generic company for emerging market commercialization can recover a portion of the development investment at low incremental cost.<\/p>\n\n\n\n

7.4 Strategic Recommendations for IP Teams and Portfolio Managers<\/strong><\/h3>\n\n\n\n

IP teams and portfolio managers should approach chiral switch programs with a structured decision framework that applies the kill screen criteria at pre-IND stage, not post-Phase 2. Programs that survive the kill screen require a clinical development plan that addresses FDA, G-BA, and NICE requirements in a single integrated Phase 3 design. The manufacturing scale-up plan must include a validated ee specification and shelf-life stability program before Phase 3 initiation.<\/p>\n\n\n\n

Commercial strategy for surviving switch candidates should include explicit payer engagement from Phase 2 — payer advisory boards should review the adverse event differentiation data before Phase 3 protocols are finalized, not as a post-Phase 3 market access exercise. HEOR modeling should begin at Phase 2, with utility mapping conducted prospectively using validated PRO instruments embedded in the Phase 3 trial, rather than retrospectively using published literature utility values.<\/p>\n\n\n\n

Patent claim drafting should extend beyond the enantiomer composition claim to include salt form, crystalline polymorph, formulation, method-of-use, and manufacturing process claims from filing day one. IPR vulnerability assessment at PTAB should be conducted annually for all Orange Book-listed patents once generic ANDA filers begin entering the market, given that PTAB invalidation rates for pharmaceutical composition patents remain above 50 percent in contested proceedings.<\/p>\n\n\n\n

For portfolio managers, the signal that a chiral switch program is commercially viable is not the 505(b)(2) regulatory approval itself — it is the combination of a positive G-BA ‘zusatznutzen’ rating and a NICE ICER below \u00a330,000 per QALY, backed by a patent cluster with at least two Orange Book-listed patents that have been assessed as IPR-resistant. Absent that combination, the program’s commercial value in Europe is essentially zero, and the U.S. commercial value is subject to IRA negotiation risk from year nine onward.<\/p>\n\n\n\n

Key Takeaways — Section 7<\/strong><\/p>\n\n\n\n

The surviving commercial model for chiral switches requires mechanistic adverse event attributability, a feasible single Phase 3 trial design that satisfies FDA, G-BA, and NICE simultaneously, and a patent cluster with assessed IPR resistance. Emerging markets offer a separate, lower-value commercial logic for switches that fail the developed-market pricing screen. Prospective HEOR modeling with PRO instruments embedded in Phase 3 trials is the single highest-return investment a switch program can make in its clinical development phase.<\/p>\n\n\n\n

Investment Strategy — Section 7<\/strong><\/p>\n\n\n\n

The most valuable chiral switch programs in 2025 are those in CNS therapeutic areas with mechanistically attributed adverse event differentiation, a completed or in-progress G-BA pre-submission scientific advice meeting, and an Orange Book patent cluster covering enantiomer composition, preferred salt or polymorph, and at least one method-of-use claim. Programs meeting these criteria in a company with a market cap under $2 billion represent genuine pipeline value that may be discounted by generalist investors who apply a blanket ‘incremental innovation’ discount to all lifecycle management strategies. Programs that do not meet these criteria — particularly cardiovascular switches in therapeutic areas saturated by generic competition — should be treated as carrying near-zero European commercial value regardless of their U.S. FDA approval status.<\/p>\n","protected":false},"excerpt":{"rendered":"

Executive Summary Chiral switching built billion-dollar franchises in the 1990s and early 2000s. The model was straightforward: isolate the active […]<\/p>\n","protected":false},"author":1,"featured_media":33831,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-24188","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/24188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=24188"}],"version-history":[{"count":3,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/24188\/revisions"}],"predecessor-version":[{"id":38458,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/24188\/revisions\/38458"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/33831"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=24188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=24188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=24188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}